{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:19:06Z","timestamp":1791235146137,"version":"4.1.0"},"reference-count":52,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2003,11,25]],"date-time":"2003-11-25T00:00:00Z","timestamp":1069718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2004,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The prostate is an androgen\u2010regulated organ and polymorphisms in genes involved in testosterone synthesis, in particular, <jats:italic>SRD5A2<\/jats:italic> (A49T and V89L variants<jats:italic>)<\/jats:italic>, <jats:italic>CYP17<\/jats:italic> (MspAI variant<jats:italic>)<\/jats:italic>, and the <jats:italic>AR<\/jats:italic> (CAG, GGC repeats), represent candidate risk factors for prostate cancer incidence and aggressiveness.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>We evaluated the relationship between these five polymorphisms and prostate cancer risk in a family\u2010based case\u2010control study (N\u2009=\u2009920). Cases were diagnosed at major medical institutions in Cleveland Ohio, and Detroit Michigan, and their unaffected brothers were used as controls. Associations were investigated with regard to prostate cancer risk, and clinical characteristics at diagnosis (i.e., tumor stage\/grade, age, family history).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The SRD5A2 V89L variant was associated with an increased risk of prostate cancer (OR\u2009=\u20091.56, <jats:italic>P<\/jats:italic>\u2009=\u20090.02). This association was driven primarily by men diagnosed at an earlier age (OR\u2009=\u20092.35, <jats:italic>P<\/jats:italic>\u2009=\u20090.001), or with more aggressive disease (OR\u2009=\u20091.63, <jats:italic>P<\/jats:italic>\u2009=\u20090.06). None of the other variants exhibited noteworthy associations with disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>These findings suggest that the SRD5A2 V89L variant may influence risk of developing prostate cancer, especially among men with a younger age of diagnosis or more aggressive disease. \u00a9 2003 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pros.10358","type":"journal-article","created":{"date-parts":[[2004,2,26]],"date-time":"2004-02-26T20:33:46Z","timestamp":1077827626000},"page":"69-76","source":"Crossref","is-referenced-by-count":73,"title":["Association of prostate cancer risk and aggressiveness to androgen pathway genes: <i>SRD5A2<\/i>, <i>CYP17<\/i>, and the <i>AR<\/i>"],"prefix":"10.1002","volume":"59","author":[{"given":"Mine S.","family":"Cicek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David V.","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillippa J.","family":"Neville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela L.","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Casey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,11,25]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10593"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00184606"},{"issue":"20","key":"e_1_2_1_4_2","first-page":"4497","article-title":"Androgen metabolism and prostate cancer: Establishing a model of genetic susceptibility","volume":"58","author":"Ross RK","year":"1998","journal-title":"Cancer Res"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010901)92:5<1130::AID-CNCR1430>3.0.CO;2-B"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1047-2797(01)00310-6"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/3.10.1873"},{"key":"e_1_2_1_8_2","first-page":"1081","volume-title":"The physiology of reproduction","author":"Coffey DS","year":"1988"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950401)75:7 <1778::AID-CNCR2820751605>3.0.CO;2-J"},{"issue":"6","key":"e_1_2_1_10_2","first-page":"1020","article-title":"A prevalent missense substitution that modulates activity of prostatic steroid 5alpha\u2010reductase","volume":"57","author":"Makridakis N","year":"1997","journal-title":"Cancer Res"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)11282-5"},{"issue":"23","key":"e_1_2_1_12_2","first-page":"5878","article-title":"The V89L polymorphism in the 5alpha\u2010reductase type 2 gene and risk of prostate cancer","volume":"59","author":"Febbo PG","year":"1999","journal-title":"Cancer Res"},{"issue":"6","key":"e_1_2_1_13_2","first-page":"1626","article-title":"Association of SRD5A2 genotype and pathological characteristics of prostate tumors","volume":"60","author":"Jaffe JM","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200007000-00004"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.10119"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)00928-6"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20000801)87:3<434::AID-IJC19>3.0.CO;2-G"},{"issue":"7","key":"e_1_2_1_18_2","first-page":"743","article-title":"The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer","volume":"10","author":"Haiman CA","year":"2001","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/20.9.1727"},{"issue":"9","key":"e_1_2_1_20_2","first-page":"943","article-title":"Cyp17 promoter variant associated with prostate cancer aggressiveness in African\u2010Americans","volume":"10","author":"Kittles RA","year":"2001","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20010601)92:5<683::AID-IJC1255>3.0.CO;2-4"},{"issue":"3","key":"e_1_2_1_22_2","first-page":"243","article-title":"A polymorphism in the CYP17 gene and risk of prostate cancer","volume":"11","author":"Stanford JL","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"20","key":"e_1_2_1_23_2","first-page":"5710","article-title":"Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect","volume":"60","author":"Habuchi T","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199910000-00010"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1093-184"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/22.15.3181"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/4.4.523"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.11.3777"},{"issue":"9","key":"e_1_2_1_29_2","first-page":"1937","article-title":"The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer","volume":"55","author":"Irvine RA","year":"1995","journal-title":"Cancer Res"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.7.3320"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.2.166"},{"issue":"6","key":"e_1_2_1_32_2","first-page":"1194","article-title":"Polymorphic repeats in the androgen receptor gene: Molecular markers of prostate cancer risk","volume":"57","author":"Stanford JL","year":"1997","journal-title":"Cancer Res"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.12.4400"},{"issue":"9","key":"e_1_2_1_34_2","first-page":"1599","article-title":"Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer","volume":"3","author":"Hakimi JM","year":"1997","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5200298"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19991022)84:5<458::AID-IJC2>3.0.CO;2-Y"},{"issue":"10","key":"e_1_2_1_37_2","first-page":"1033","article-title":"Androgen receptor polymorphisms and the incidence of prostate cancer","volume":"11","author":"Chen C","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_2_1_38_2","first-page":"928","article-title":"CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer","volume":"12","author":"Plummer SJ","year":"2003","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"e_1_2_1_39_2","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/oxfordjournals.aje.a113948","article-title":"Excluding controls: Misapplications in case\u2010control studies","volume":"120","author":"Lubin JH","year":"1984","journal-title":"Am J Epidemiol"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a010051"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009877"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200206000-00006"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.1789"},{"issue":"10","key":"e_1_2_1_45_2","first-page":"945","article-title":"Inherited genotype and prostate cancer outcomes","volume":"11","author":"Rebbeck TR","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"e_1_2_1_46_2","first-page":"120","article-title":"Association of the CYP17 gene polymorphism with the risk of prostate cancer: A meta\u2010analysis","volume":"12","author":"Ntais C","year":"2003","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010815)92:4<941::AID-CNCR1404>3.0.CO;2-P"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690746"},{"issue":"4","key":"e_1_2_1_49_2","first-page":"439","article-title":"The polymorphic exon 1 androgen receptor CAG repeat in men with a potential inherited predisposition to prostate cancer","volume":"9","author":"Lange EM","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"e_1_2_1_50_2","first-page":"379","article-title":"The androgen receptor gene GGN microsatellite and prostate cancer risk","volume":"7","author":"Platz EA","year":"1998","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.2990170409"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0895-827"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0295-99"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.10358","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.10358","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T05:24:21Z","timestamp":1700198661000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.10358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11,25]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["10.1002\/pros.10358"],"URL":"https:\/\/doi.org\/10.1002\/pros.10358","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,11,25]]}}}